Artelo Biosciences (ARTL) investor relations material

Executive summary

• Achieved positive first-in-human Phase 1 data for ART26.12, showing favorable safety and pharmacokinetics, with preparations underway for a multiple ascending dose study in Q3 2026.

• Interim Phase 2 CARES data for ART27.13 demonstrated improvements in body weight, lean body mass, and physical activity in cancer anorexia-cachexia patients, with a favorable side-effect profile.

• Received favorable UK MHRA regulatory guidance for ART12.11, supporting Phase 1 study plans and potential accelerated pathways, with human studies planned for early 2027.

• Secured a Notice of Allowance from the European Patent Office for ART27.13, extending patent protection through December 2041.

Financial highlights

• Research and development expenses were $5.4 million for 2025, down from $6.0 million in 2024.

• General and administrative expenses increased to $6.0 million in 2025 from $4.1 million in 2024.

• Net loss for 2025 was $12.9 million, or $12.52 per share, compared to $9.8 million in 2024.

• Cash and investments totaled $0.6 million as of December 31, 2025.

Outlook and guidance

• Multiple ascending dose study for ART26.12 expected to begin enrollment in Q3 2026.

• Human clinical studies for ART12.11 planned for the first half of 2027, pending toxicology results.

• Focus remains on disciplined clinical execution, strategic collaboration, and prudent capital management.